AstraZeneca: Imfinzi+bevacizumab met primary endpoint for PFS in liver cancer

First global Phase III trial to show improved clinical outcome for systemic therapy in combination with transarterial chemoembolization TACE in this setting Positive high-level results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI or durvalumab in combination with transarterial chemoembolization TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival PFS versus TACE alone in patients with hepatocellular carcinoma HCC eligible for embolization. The trial continues to follow the secondary endpoint of overall survival OS . Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “These positive results for IMFINZI-based treatment in EMERALD-1 may bring the potential of immunotherapy to patients with earlier stages of liver cancer. We look forward to discussing these data with regulatory authorities and seeing the survival data mature over time, which will be important as we aim to bring this novel treatment option to patients.” The safety profiles for IMFINZI and TACE plus bevacizumab were consistent with the known profile of each medicine, and there were no new safety findings. The data will be presented at a forthcoming medical meeting and shared with regulatory authorities.